In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT).
You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations.
Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes.
What you will learn:
- Global opportunities created by advanced therapies in drug discovery
- How sustainable growth is in this area and what the research sector should be focussing on for future success
- The challenges this sector faces
- Key trends for this sector
An audience Q&A session with the presenters will follow the webinar presentation.